CR7606A - Derivados de bisindolil-maleimida como inhibidores de cinasa - Google Patents
Derivados de bisindolil-maleimida como inhibidores de cinasaInfo
- Publication number
- CR7606A CR7606A CR7606A CR7606A CR7606A CR 7606 A CR7606 A CR 7606A CR 7606 A CR7606 A CR 7606A CR 7606 A CR7606 A CR 7606A CR 7606 A CR7606 A CR 7606A
- Authority
- CR
- Costa Rica
- Prior art keywords
- kinase
- bisindolil
- maleimida
- derivatives
- methods
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 3
- 102000020233 phosphotransferase Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- DXGTUUQHTDOFFQ-UHFFFAOYSA-N [N].C1=CC=C2NC=CC2=C1 Chemical group [N].C1=CC=C2NC=CC2=C1 DXGTUUQHTDOFFQ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 abstract 1
- 150000003236 pyrrolines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38593502P | 2002-06-05 | 2002-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR7606A true CR7606A (es) | 2009-01-16 |
Family
ID=29736126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR7606A CR7606A (es) | 2002-06-05 | 2004-12-06 | Derivados de bisindolil-maleimida como inhibidores de cinasa |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6987110B2 (https=) |
| EP (1) | EP1513830A1 (https=) |
| JP (1) | JP2005531609A (https=) |
| KR (1) | KR20050008787A (https=) |
| CN (1) | CN1671694A (https=) |
| AU (1) | AU2003238874A1 (https=) |
| BR (1) | BR0311821A (https=) |
| CA (1) | CA2488602A1 (https=) |
| CR (1) | CR7606A (https=) |
| IL (1) | IL165515A0 (https=) |
| MX (1) | MXPA04012188A (https=) |
| NO (1) | NO20045699L (https=) |
| RU (1) | RU2004135382A (https=) |
| WO (1) | WO2003104222A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL156339A0 (en) | 2000-12-08 | 2004-01-04 | Ortho Mcneil Pharm Inc | Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| ES2300573T3 (es) * | 2002-05-08 | 2008-06-16 | Janssen Pharmaceutica Nv | Inhibidores de cinasa sustituidos con pirrolina. |
| DE60323749D1 (de) * | 2002-06-05 | 2008-11-06 | Janssen Pharmaceutica Nv | Substituierte pyrroline als kinase inhibitoren |
| CA2393720C (en) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| AU2002951253A0 (en) * | 2002-09-06 | 2002-09-19 | Medvet Science Pty. Ltd. | A method of modulating cellular activity |
| CA2520590A1 (en) * | 2003-03-27 | 2004-11-04 | Janssen Pharmaceutica, N.V. | Substituted pyrroline kinase inhibitors |
| CA2529353A1 (en) * | 2003-06-13 | 2005-01-06 | Janssen Pharmaceutica N.V. | Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors |
| US20080050314A1 (en) * | 2004-02-26 | 2008-02-28 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b) |
| WO2005095983A1 (en) * | 2004-03-04 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with protein kinase c, gamma (prkcg) |
| RU2413511C2 (ru) * | 2004-04-08 | 2011-03-10 | Новартис Аг | Ингибиторы протеинкиназы с, предназначенные для лечения аутоиммунных заболеваний и отторжения трансплантата |
| JP2007532506A (ja) * | 2004-04-08 | 2007-11-15 | ノバルティス アクチエンゲゼルシャフト | 自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼｃ阻害剤 |
| US20060079568A1 (en) * | 2004-05-21 | 2006-04-13 | The Texas A&M University System | Inhibition of atherosclerosis by diindolylmethane analogs |
| EP1662259A1 (en) * | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| CA2613889A1 (en) * | 2005-06-08 | 2006-12-14 | Centocor, Inc. | A cellular therapy for ocular degeneration |
| AU2006268908A1 (en) | 2005-07-11 | 2007-01-18 | Novartis Ag | Indolylmaleimide derivatives |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US20070088019A1 (en) * | 2005-09-29 | 2007-04-19 | Han-Cheng Zhang | Macroheterocyclic compounds as kinase inhibitors |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20090324610A1 (en) * | 2006-04-25 | 2009-12-31 | Kyushu Univeristy, National University Corporation | Gene associated with arteriosclerotic disease, and use thereof |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2008063278A (ja) * | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | １−ピリジン−４−イル−インドール類の製造方法 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| CA3114827C (en) | 2007-07-31 | 2023-09-05 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic endocrine |
| EP2229434B1 (en) | 2007-11-27 | 2011-09-07 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| FR2927075A1 (fr) * | 2008-02-04 | 2009-08-07 | Centre Nat Rech Scient | Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes |
| KR101731474B1 (ko) | 2008-02-21 | 2017-05-11 | 얀센 바이오테크 인코포레이티드 | 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물 |
| US8623648B2 (en) * | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| US20090291982A1 (en) * | 2008-05-22 | 2009-11-26 | Astrazeneca Ab | New Substituted Oxindole Derivative 352 |
| EP2318516A1 (en) * | 2008-06-30 | 2011-05-11 | Centocor Ortho Biotech Inc. | Differentiation of pluripotent stem cells |
| PL2310492T3 (pl) | 2008-06-30 | 2015-12-31 | Janssen Biotech Inc | Różnocowanie pluripotencjalnych komórek macierzystych |
| US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
| MX349178B (es) * | 2008-10-31 | 2017-07-17 | Centocor Ortho Biotech Inc | Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático. |
| PL2346988T3 (pl) * | 2008-10-31 | 2017-10-31 | Janssen Biotech Inc | Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki |
| ES2584053T3 (es) * | 2008-11-20 | 2016-09-23 | Janssen Biotech, Inc. | Métodos y composiciones para la unión de células y cultivo en sustratos planos |
| ES2642070T3 (es) | 2008-11-20 | 2017-11-15 | Janssen Biotech, Inc. | Cultivo de células madre pluripotentes en microportadores |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2456859A4 (en) | 2009-07-20 | 2015-03-18 | Janssen Biotech Inc | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS |
| KR102058901B1 (ko) | 2009-07-20 | 2019-12-24 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| SG177483A1 (en) | 2009-07-20 | 2012-02-28 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
| ES2665006T3 (es) * | 2009-10-29 | 2018-04-24 | Janssen Biotech, Inc. | Células madre pluripotentes |
| CA2784425A1 (en) * | 2009-12-23 | 2011-06-30 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
| SG181687A1 (en) | 2009-12-23 | 2012-07-30 | Centocor Ortho Biotech Inc | Differentiation of human embryonic stem cells |
| EP2542667A4 (en) | 2010-03-01 | 2013-07-31 | Janssen Biotech Inc | PROCESS FOR CLEANING CELLS OBTAINED FROM PLURIPOTENTIAL STEM CELLS |
| RU2663339C1 (ru) | 2010-05-12 | 2018-08-03 | Янссен Байотек, Инк. | Дифференцирование эмбриональных стволовых клеток человека |
| CN103221536B (zh) | 2010-08-31 | 2016-08-31 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
| ES2658146T3 (es) | 2010-08-31 | 2018-03-08 | Janssen Biotech, Inc. | Diferenciación de células madre embrionarias humanas |
| EP2611907B1 (en) | 2010-08-31 | 2016-05-04 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
| ES2387359B1 (es) * | 2011-02-25 | 2013-08-01 | Consejo Superior De Investigaciones Científicas (Csic) | Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos |
| KR102203056B1 (ko) | 2011-12-22 | 2021-01-14 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화 |
| HK1206058A1 (en) | 2012-03-07 | 2015-12-31 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
| AU2013271581B2 (en) | 2012-06-08 | 2018-08-09 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
| JP6557147B2 (ja) | 2012-12-31 | 2019-08-07 | ヤンセン バイオテツク，インコーポレーテツド | Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化 |
| BR112015015770A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas |
| RU2687379C2 (ru) | 2012-12-31 | 2019-05-13 | Янссен Байотек, Инк. | Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| US10006006B2 (en) | 2014-05-16 | 2018-06-26 | Janssen Biotech, Inc. | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells |
| DK3443073T3 (da) | 2016-04-14 | 2024-09-02 | Janssen Biotech Inc | Differentiering af pluripotente stamceller til intestinale mellemtarmendodermceller |
| CN109535158B (zh) * | 2016-04-26 | 2021-04-23 | 浙江工业大学 | 一种双芳基马来酰亚胺类化合物及其药学上可接受的盐及其制备方法和应用 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ280738B6 (cs) | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
| GB8904161D0 (en) | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| ES2236702T3 (es) | 1993-12-23 | 2005-07-16 | Eli Lilly And Company | Inhibidores de la proteina quinasa c. |
| EP0888339A4 (en) | 1996-03-20 | 2001-02-28 | Lilly Co Eli | SYNTHESIS OF INDOLYLMALEINIMIDES |
| SE9603283D0 (sv) * | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
| AU2548699A (en) * | 1998-02-23 | 1999-09-06 | Rei Asakai | Cell death inhibitors |
| CA2338866A1 (en) | 1998-07-30 | 2000-02-10 | Japan Tobacco Inc. | Disubstituted maleimide compound and pharmaceutical use thereof |
| ATE284387T1 (de) | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| YU4403A (sh) | 2000-07-27 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati 3-indolil-4-fenil-1h-pirol-2,5-diona, kao inhibitori glikogen sintaza kinaze-3 beta |
| AU2002221810B2 (en) | 2000-11-07 | 2005-06-23 | Novartis Ag | Indolylmaleimide derivatives as protein kinase C inhibitors |
-
2003
- 2003-06-04 MX MXPA04012188A patent/MXPA04012188A/es unknown
- 2003-06-04 EP EP03734389A patent/EP1513830A1/en not_active Withdrawn
- 2003-06-04 RU RU2004135382/04A patent/RU2004135382A/ru not_active Application Discontinuation
- 2003-06-04 CA CA002488602A patent/CA2488602A1/en not_active Abandoned
- 2003-06-04 JP JP2004511292A patent/JP2005531609A/ja not_active Withdrawn
- 2003-06-04 CN CNA038184788A patent/CN1671694A/zh active Pending
- 2003-06-04 US US10/454,069 patent/US6987110B2/en not_active Expired - Fee Related
- 2003-06-04 WO PCT/US2003/017569 patent/WO2003104222A1/en not_active Ceased
- 2003-06-04 KR KR10-2004-7019678A patent/KR20050008787A/ko not_active Withdrawn
- 2003-06-04 AU AU2003238874A patent/AU2003238874A1/en not_active Abandoned
- 2003-06-04 BR BR0311821-5A patent/BR0311821A/pt not_active IP Right Cessation
-
2004
- 2004-12-02 IL IL16551504A patent/IL165515A0/xx unknown
- 2004-12-06 CR CR7606A patent/CR7606A/es unknown
- 2004-12-29 NO NO20045699A patent/NO20045699L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04012188A (es) | 2005-07-25 |
| BR0311821A (pt) | 2005-04-05 |
| CN1671694A (zh) | 2005-09-21 |
| US20040059113A1 (en) | 2004-03-25 |
| CA2488602A1 (en) | 2003-12-18 |
| AU2003238874A1 (en) | 2003-12-22 |
| NO20045699L (no) | 2005-01-28 |
| US6987110B2 (en) | 2006-01-17 |
| WO2003104222A1 (en) | 2003-12-18 |
| RU2004135382A (ru) | 2005-06-27 |
| IL165515A0 (en) | 2006-01-15 |
| EP1513830A1 (en) | 2005-03-16 |
| JP2005531609A (ja) | 2005-10-20 |
| KR20050008787A (ko) | 2005-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR7606A (es) | Derivados de bisindolil-maleimida como inhibidores de cinasa | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| BRPI0411366A (pt) | derivados de indazolil (indolil) maleimida substituìdos como inibidores de cinase | |
| GB0510141D0 (en) | Novel compounds B3 | |
| SE0303180D0 (sv) | Novel compounds | |
| SE0302232D0 (sv) | Novel Compounds | |
| NO20044221L (no) | Nye forbindelser | |
| NO20073958L (no) | Pyrrolidylderivater av heteroaromatiske forbindelser som fosfodiesteraseinhibitorer | |
| ECSP11011284A (es) | Inhibidores de Poli (ADP-ribosa) Polimerasa (PARP) | |
| MX2009005252A (es) | Aminopirrolidinas como antagonistas del receptor de quimiocina. | |
| WO2005123703A8 (en) | Alkynyl derivatives as modulators of metabotropic glutamate receptors | |
| EA201000149A1 (ru) | Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз | |
| NO20060544L (no) | Enzymatiske prosesser for produksjon av 4-substituerte 3-hydroksysmorsyrederivater og naerliggende cyano, hydroksy substituerte karboksylsyre estere | |
| CR10766A (es) | Inhibidores de metaloproteasa derivados de heterociclicos | |
| UA90706C2 (ru) | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний | |
| UA83875C2 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
| EA201001481A1 (ru) | Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4 | |
| EA200701588A1 (ru) | Способы получения замещённых фенилпиразолмочевин | |
| MX2007011847A (es) | Derivados de pirimidindiona como antagonistas del receptor de procineticina 2. | |
| ATE432260T1 (de) | Pyridinderivate als pkc-theta-hemmer | |
| NO20081617L (no) | Metoder for fremstilling av Glutaminsyrederivater | |
| EA200601441A1 (ru) | Способ получения соединений замещённого триазола | |
| ECSP056193A (es) | Derivados sustituidos del pirrol | |
| WO2007014008A3 (en) | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |